The cell surface glycoprotein CD8 functions as a coreceptor with the TCR on cytotoxic T lymphocytes. Mutational analysis of the binding site of CD8 for MHC class I predicted that distinct surfaces of CD8 would interact with both the a2 and a3 domains of class I. Using a cell-cell adhesion assay, we identified three residues Q115, D122, and E128 in the or2 domain of class I critical for interaction with CD8. The side chains of these residues point towards a cavity formed by the 0tl/e~2 platform, the or3 domain and [32-microglobulin ([32m) of class I. These residues were predicted to contact CD8 based on a bivalent model of interaction between one CD8o~/oL homodimer and two MHC class I molecules. These results therefore provide support for the model.
M
HC class I molecules are highly polymorphic proteins that bind antigenic peptides and present them to T cells. The functional interaction of cytotoxic T cells with antigen-presenting cells requires the engagement oft cell receptor, in concert with CD8, with the MHC/peptide complex (1, 2) . Following a large body of evidence suggesting a central role of CD8 in T cell signaling, activation and thymic selection, much interest has centered on the characterization of interaction between various components involved in T cell recognition (3, 4) . It has become clear that whereas the TCK binds to the or1 and r domains of a class I-peptide complex, CD8 binds directly to the or3 domain (5-9).
A soluble form of CD8ot/ot homodimer was crystallized and its two Ig-like domains were found to share many structural similarities with their Ig counterparts (10) . Mutational analysis of CD8ot/ot revealed that unlike Ig molecules in which the surface containing the CDR loops is exclusively used to recognize antigen, distinct surfaces of CD8ot/c~, one containing the CDR-like loops and the other comprised of the A and B {3-strands, interact with class I (11) . The discovery ofa non-CDR surface as an important contact area on CD8ot led us to postulate that CD8 interacted not only with the ~t3 domain but also with the or2 domain of class I. To test this hypothesis, we performed site-specific mutagenesis of class I and analyzed the mutants using a cell-cell adhesion assay (12) . We identified three critical residues in the 0~2 domain, two located underneath the peptide-binding floor and one on a nearby loop, all with the side chains pointing towards a cavity (13) . Thus, CD8o~/ot appears to interact both with the or2 and o~3 domain of MHC class I.
Materials and Methods
Construction of Mutant HLA-A2 cDNAs. Site-specific mutagenesis was performed as described (14) using a cDNA template encoding HLA-A2010 (15) . All mutations were confirmed by sequencing a 430 bp PflMI/NdeI fragment of the HLA-A2 gene encoding the c~2 domain (NdeI/SmaI fragment encoding cx3 in Q226A). Fragments were inserted into corresponding sites of wild type HLA-A2 in pBluescript II. HLA-A2 mutants were then subcloned into NotI/SalI sites in the plasmid vector EBO-pLPP containing an hygromycin B resistance gene (16) .
Cells and Antibodies. C1R is a B cell line that lacks endogenous HLA-A, B genes thus expresses virtually no class I products.
Wild-type and mutant A2 cDNA constructs were electroporated into CIR cells 960 IxF 250V (17) . All A2 transfectants (C1R-A2) were maintained in hygromycin B at 600-1,000 p,g/ml, depending on levels of HLA-A2 expression. CHO cells either transfected (MT8.02) or mock transfected (MT8.C13) with the CD8 c~-chain gene were provided by R. Salter (University of Pittsburgh) (12 Binding Assay of Mutant CD8ee to Class L The cell-cell binding assay was performed as described (11) . Briefly, COS-7 cells firmly attached to a tissue culture dish were transfected using lipofectamine (Life Technologies, Inc., Grand Island, NY) with wild-type or mutant forms of CD8o~. CD8c~ transfectants were tested for their ability to bind to the MHC class I + cell line UC (19) . Since these UC cells were modified to constitutively express the firefly luciferase gene, the number of bound cells was determined by measuring the amount of luciferase activity in the cell extract. Expression levels of CD8 in COS-7 cells were checked in every experiment by flow cytometry of cells stained with FITC-conjugated mAb OKT-8 and Leu2a. Since the levels of cell surface expression varied slightly among wild-type and mutant forms of CD8, the binding of UC cells was normalized according to the following formula: 100 
Results and Discussion
To examine the effects of class I mutations on binding to CD8, we substituted an alanine residue in several areas within the 0~2 domain of class I. The majority of residues chosen for mutagenesis was based on our model of CD8 and class I interaction (11) . All positions were surface accessible and many of them well conserved, reasoning that these residues are most likely to make contact with the class I molecule without rendering global structural alterations. Amino acids Ql15 and D122 are on the peptide-binding floor with their side chains pointing away from the cleft (Fig. 1 a) . Residues K127, E128, and D129 are located on the loop connecting [~-strands 3 and 4 ($3 and $4) whereas $123, T134, and D137 are all on nearby $4. Another set of mutations, D102, Ll10, and Rlll all located near the junction of $1 and $2, were based upon another molecular docking model (21) . Residues E89 and E173 were chosen as potential controls for their likely inability to bind to CD8 based on our model. Wild-type and mutant forms of an HLA-A2 cDNA were subcloned into an EBO expression vector and transfected into C1R cells that lack endogenous HLA-A, B genes (17) . All CIR-A2 mutants except for D129 expressed high levels of HLA-A2 with mean fluorescence intensities ranging from 90-110% of the wildtype transfectant (Fig. 1 b) .
The A2 transfectants were tested for binding to CHO cells expressing the human CD8ci gene, using a cell-cell adhesion assay. As shown in Fig. 2 a, fluorescence-labeled wild-type transfectants bound to the CD8 + CHO cell monolayer to near saturation. The binding of HLA-A2 C1R transfectants to the CD8 + CHO cells was mediated specifically by MHC class I and CD8 molecules since this interaction can be exclusively and completely inhibited by either anti-class I or anti-CD8 mAbs (5, 12). We included two mutants, A245V and Q226A of HLA-A2 as negative controls since these mutations in the 0~3 domain were previously shown to be responsible for negative CD8 binding phenotypes (5, 6). Neither of these two mutant transfectants bound to the CD8 + CHO cells (Fig. 2, a and b) .
Mutations at Ql15, D122, and E128 showed no specific binding to CD8 (Fig. 2, a and b) . This effect can not be attributed to levels of HLA-A2 expression by the various transfectants, since expression levels of the non-binders were equal to or greater than at least one of the CD8 binders ( Fig. 1 b and data not shown). To exclude possible indirect effects on the o~3 domain by conformational changes, we stained all mutants with mAb TP25.99 that binds specifically to the oL3 domain of class I where the critical CD8 binding loop was located (22) . Staining of all mutants with TP25.99 was similar to the wild-type transfectant (data not shown). These results suggest direct involvement of these three residues in contacting CD8 cx-chain. While E128 appeared critical in binding, mutations at nearby K127 or distant E89 and E173 did not affect the interaction. Mutations $132A, T134A, and D137A on $4 did not affect binding (Fig. 2, a and b) , nor did the exposed junction near $1 and $2 (D102A, L110A, R111A, and D102A/RlllA), indicating that much of other exposed areas on the o~2 domain of class I is not likely to be critical for interacting with CD8. Since our analysis did not score mutations that simultaneously resulted in a loss of surface expression and a reduced affinity for CD8 (i.e., D129, data not shown), the data resulted in description of only a group of critical residues. In cocrystals of human growth hormone and its receptor, a few contact amino acids clustered in a central region accounted for 85% of the binding free energy resulting from the alanine substitutions whereas all peripheral residues only contributed to 15% of the binding free energy (23) .
To further define the A/B surface of CD8 that may contact the oe2 domain of MHC class I, we mutated several solvent accessible residues on the A, B, and G 13-strands of human CD8 to alanine. Once CD8 mutants were generated, a transient cell-cell adhesion assay was employed as described (11) . In this assay, COS 7 cells expressing CD8 mutants were tested for their ability to bind to the class I + cell line UC that carries a firefly luciferase gene. Replacement of R4 with a similarly positively-charged lysine also resulted in complete inhibition of binding (Fig. 3, p. 1279 ) (11) . Alanine substitution at Q23 on the B strand had a
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CD8 Interaction with the el2 and cr Domains of MHC Class I similar effect, suggesting that this residue may participate in the interaction as part of the R4/L25 surface of CD8. The effect of mutations in other positions on binding ranged from moderately-affected (L8, E19, and T47) to unaffected (D9 and H106). It appeared that only a small number of residues on the CD8 A and B but not the G J3-strands were critical to the interaction with the or2 domain of MHC class I. Examination of the crystal structure of HLA-A2 reveals a large open cavity on the molecular surface (Fig. 4, a and b) . The cavity is composed of the 0Uot2 platform, the loops of the or3 domain and a part of J32m with the CD8 contact residues all on one side of this cavity. About one-third of the underside of the 0tlot2 13-sheet constituting the floor of the groove is exposed to this space (13) . Residues Ql15 and D122 are both located on the floor of the peptidebinding groove with their side chains pointing down towards this cavity (Fig. 4 a) . Residues Ql15, D122 and E128 are completely conserved in 22 human (24, 25) and 12 murine (26) sequences. Our results are supported by the observation that murine primary CD8 + T cells responded more vigorously to an HLA-A2 hybrid with the murine et20t3 domain than with only the murine 0t3 domain (27) . The impact of the or2 domain of class I on recognition by 1277 Sun et al.
CD8 + T cells is further supported by a recent study in which CTL responses in human CD8 transgenic mice to an A2/k b hybrid molecule (human etlet2 domain, murine 0t3 domain) were markedly enhanced compared to responses in nontransgenic mice. These results provide functional evidence for a second interaction site outside of the or3 domain that is essential for optimal coreceptor function (28) . In experiments discounting the involvement of the or2 domain in binding CD8, most positions tested for binding were either polymorphic or on the upper faces of the etlcx2 domains (5, 6). Interestingly, two of the three critical residues in the or2 domain of class I found in this study were negatively charged whereas residue R4 on the lateral side of CD8 was positively charged. This charge complementarity coincides with that of the contact surface between the or3 loop of class I and the CDR-like regions of CD8, supporting a crucial role for electrostatic interactions between CD8 and class I molecules (6, 11). Previous work on the interaction between CD8 and MHC class I had implicated the importance of the CDRlike loops of CD8 and the or3 domain of class I (5, 20). Our results extend this interaction to include the or2 domain of class I interacting with the A/B surface of CD8. A CD8ct/ ot homodimer would fit into the class I/J32m cavity through (12) . A2 transfectants were grouped based on their locations on the surface of class I molecule. Results from three experiments were averaged (E173A from two experiments) and were expressed relative to wild-type binding. S132, T134, and D137 transfected C 1 R cells were grown in RPMI 1640 tissue culture medium. Error bars represent SE. For each mutant, 2-6 repeated assays gave similar results, The binding assay was conducted in double blind fashion. D129A showed a significant loss of binding (15-20% of wild type), but due to its noticeable toss of expression level on C1R cells (75% mean fluorescence intensity of wild type), results were not included in the figure. part of its CDR-like loops and the entire A/B binding surface from one monomer (Fig. 4 a) . Given this alignment, one CD8cx/o~ homodimer could interact simultaneously with two symmetrically related HLA molecules (Fig. 4 b) . Our results provide support for this model in that the three critical residues in the 0t2 domain were predicted to interact with CD8 based on the model. Assuming the model is correct, there are residues on ~2m that are likely to interact with CD8 as well. The alignment of CD8 with class l has important implications for the function of the CD8ci/ot molecule. CD8 is likely to induce dimerization of MHC class I. It has been shown that cross-linking class I led to signal transduction (29) (30) (31) (32) . Conversely, the dimerization may bridge two TCRs interacting with class I molecules, and thus promote the capping of TCR and facilitate complex formation between TCR and associated signal molecules. Such a model was proposed for T cell receptor, CD4, and MHC class II complexes based on the finding that the crystals of MHC class II molecules were dimers of dimers (33) . The CD8 molecule exists as either an or/or homodimer or ot/[3 heterodimer. Only the CD8ot/ot homodimer is expressed on a subset of human NK cells and T cell receptor ~//B cells in the gut. Both forms are present on thymocytes and peripheral T cells, however, the ot/[3 heterodimer is predominant. The heterodimer could also be bivalent by analogy with growth hormone and its receptor (23) . Growth hormone interacts through two nonidentical binding sites to nearly identical sites on two hormone receptors.
Another potential consequence of CD8 interaction with the et2 domain could be to influence the conformation of MHC peptide formed by the or1 and or2 domains. Small conformation effects might affect TCR-peptide-MHC interactions. It has been shown that small changes in peptides can significantly alter the outcome for TCR activation through differential TCR signaling (34, 35) . The requirement for CD8 in TCR triggering has generally been thought to result from increases in TCR-peptide-MHC avidity by interaction of CD8 with the et3 domain. Supporting the notion that CD8 may be doing more than just increasing avidity solely through interaction with MHC, a recent paper demonstrated a role for CD8-TCR interaction in modulating TCR-ligand interaction (36) . Our work suggests the possibility of modulation of TCR-ligand interaction through CD8-class I et2 domain interaction.
